Literature DB >> 18393797

Memapsin 2 (beta-secretase) inhibitors: drug development.

Arun K Ghosh1, Nagaswamy Kumaragurubaran, Ling Hong, Gerald Koelsh, Jordan Tang.   

Abstract

Memapsin 2 (beta-secretase, BACE 1) processing of beta-amyloid precursor protein is the first step in the pathway leading to the production of amyloid-beta, thus, it is a major target for the development of inhibitor drug for the treatment of Alzheimers's Disease. Although there are distinctive advantages of this protease as a drug target, the development of drug-like memapsin 2 inhibitors has been somewhat slow since the cloning of the protease seven years ago. Here we review the progress of memapsin 2 inhibitor development using crystal structure-based design cycles. Recent progress has evolved the inhibitors into sizes sufficiently small to penetrate cell membranes and the blood-brain barrier yet retain potency for the inhibition of Abeta production in cultured cells and experimental animals. Such progress lends optimism that clinically useful memapsin 2 inhibitors will eventually be developed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393797     DOI: 10.2174/156720508783954730

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  18 in total

1.  Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice.

Authors:  Wan-Pin Chang; Xiangping Huang; Deborah Downs; John R Cirrito; Gerald Koelsch; David M Holtzman; Arun K Ghosh; Jordan Tang
Journal:  FASEB J       Date:  2010-11-08       Impact factor: 5.191

Review 2.  New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

Authors:  Salvatore Salomone; Filippo Caraci; Gian Marco Leggio; Julia Fedotova; Filippo Drago
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

3.  Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.

Authors:  Latha Devi; Jordan Tang; Masuo Ohno
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

4.  Cu(II)-catalyzed olefin migration and Prins cyclization: highly diastereoselective synthesis of substituted tetrahydropyrans.

Authors:  Arun K Ghosh; Daniel R Nicponski
Journal:  Org Lett       Date:  2011-07-28       Impact factor: 6.005

5.  Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo.

Authors:  Hyun-Seok Hong; Sandeep Rana; Lydia Barrigan; Aibin Shi; Yi Zhang; Feimeng Zhou; Lee-Way Jin; Duy H Hua
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

6.  Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice.

Authors:  Ryoichi Kimura; Latha Devi; Masuo Ohno
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

Review 7.  Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.

Authors:  Francesco Panza; Vincenzo Solfrizzi; Vincenza Frisardi; Cristiano Capurso; Alessia D'Introno; Anna M Colacicco; Gianluigi Vendemiale; Antonio Capurso; Bruno P Imbimbo
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 8.  Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.

Authors:  Arun K Ghosh
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

Review 9.  The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential.

Authors:  Robert Vassar; Dora M Kovacs; Riqiang Yan; Philip C Wong
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

Review 10.  Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.

Authors:  Akanksha Kulshreshtha; Poonam Piplani
Journal:  Neurol Sci       Date:  2016-06-01       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.